OMT 111
Alternative Names: OMT-111Latest Information Update: 26 Dec 2022
At a glance
- Originator MetiMedi Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Metabolism-modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Colorectal cancer; Solid tumours
Most Recent Events
- 26 Dec 2022 OMT 111 is still in phase II trials for Colorectal cancer (Metastatic disease, Second-line therapy or greater, Treatment-resistant) in South Korea(SC) (KCT0005343)
- 26 Dec 2022 No development reported - Phase-II for Solid tumours (Late-stage disease, Metastatic disease) in Vietnam (Parenteral) (NCT04520386)
- 31 Oct 2020 Phase-II clinical trials in Solid tumours (Metastatic disease, Late-stage disease) in Vietnam (Parenteral) (NCT04520386 )